在"我们所有人"研究计划中的GLP-1受体激进分子处方模式
medRxiv : the preprint server for health sciences
|February 26, 2026
概括
我们所有人的研究计划
科学领域:
- 精准医学是一门精准的医学.
- 观察性健康研究 观察性健康研究
- 药理疗法 药理疗法 药理疗法
背景情况:
- 葡萄糖类-1受体激动剂 (GLP-1RAs) 越来越多地用于2型糖尿病,肥胖和睡眠呼吸暂停.
- 美国国立卫生研究院的我们所有人研究计划提供了丰富的数据集,用于对GLP-1RA利用的现实研究.
- 了解GLP-1RA在不同人群中的使用对于推进精准医学至关重要.
研究的目的:
- 为了描述参与者的特征,在"我们所有人"研究计划中规定了GLP-1RA.
- 为了证明我们所有人的数据集对研究GLP-1RA使用的有用性.
- 概述使用此资源用于未来研究的优点和局限性.
主要方法:
- 对我们所有人控制的级别精选数据库版本8 (CDRv8) 的描述性分析.
- 使用了横截面调查,纵向电子健康记录 (EHR) 和纵向Fitbit数据.
- 根据不同天至少两份处方记录确定了GLP-1RA队列.
主要成果:
- 我们所有人GLP-1RA队列包括15477名参与者,证明了高数据可用性.
- 处方GLP-1RA的参与者通常年龄较大,并且比CDRv8总体人群有更多的并发症.
- 自2014年以来,处方趋势显示GLP-1RA摄入量迅速增加.
结论:
- 我们所有人的CDRv8是对GLP-1RAs的现实世界观测研究的宝贵资源.
- 该数据集支持对大型异质队列的研究,使得未回答问题的调查成为可能.
- 未来的研究可以利用这些数据来解决GLP-1RA的使用问题,并复制来自其他来源的发现.
相关概念视频
Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
Oral Hypoglycemic Agents: Glinides
758
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
758
Dipeptidyl Peptidase 4 Inhibitors
786
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
786
Oral Hypoglycemic Agents: Biguanides and Glitazones
739
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
739
Prescription, Nonprescription and Orphan Drugs
1.3K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.3K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
672
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
672


